---
title: "Iterum Therap (ITRM.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ITRM.US.md"
symbol: "ITRM.US"
name: "Iterum Therap"
industry: "Pharmaceuticals"
datetime: "2026-05-20T01:58:07.615Z"
locales:
  - [en](https://longbridge.com/en/quote/ITRM.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ITRM.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ITRM.US.md)
---

# Iterum Therap (ITRM.US)

## Company Overview

Iterum Therapeutics plc, a pharmaceutical company, develops and commercializes treatments for drug resistant bacterial infections in Ireland, Bermuda, and the United States. The company offers ORLYNVAH, an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis microorganisms in adult women with limited or no alternative oral antibacterial treatment options. It is also developing sulopenem, a novel anti-infective compound with oral and intravenous formulations to treat uncomplicated urinatry tract infections, complicated urinary tract infections, and complicated intra-abdominal infections, as well as community-acquired bacterial pneumonia, acute bacterial prostatitis, gonococcal urethritis, and pelvic inflammatory diseases. Iterum Therapeutics plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:12.000Z

**Overall: D (0.63)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 182 / 190 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 0.00% |  |
| Net Profit YoY | 11.76% |  |
| P/B Ratio | 0.00 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 0.00 |  |
| Revenue | 390000.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 285.48% | A |
| Profit Margin | -6913.08% | E |
| Gross Margin | 94.87% | A |
| Revenue YoY | 0.00% | D |
| Net Profit YoY | 11.76% | C |
| Total Assets YoY | 104.11% | A |
| Net Assets YoY | 35.86% | A |
| Cash Flow Margin | 72.38% | C |
| OCF YoY | 0.00% | D |
| Turnover | 0.02 | E |
| Gearing Ratio | 122.71% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Iterum Therap",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "0.00%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "11.76%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "0.00",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "0.00",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "390000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "285.48%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "-6913.08%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "94.87%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "11.76%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "104.11%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "35.86%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "72.38%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Turnover",
          "value": "0.02",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "122.71%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.14 | 65/190 | - | - | - |
| PB | -0.50 | 206/190 | - | - | - |
| PS (TTM) | 9.54 | 92/190 | 47.44 | 37.23 | 9.54 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Cormedix (CRMD.US) | A | A | B | C | B | A |
| 02 | Eli Lilly (LLY.US) | A | A | B | D | B | B |
| 03 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | B | B |
| 04 | Roche (RHHBY.US) | A | B | B | D | B | B |
| 05 | AstraZeneca (AZN.US) | A | B | C | D | B | B |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/ITRM.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/ITRM.US/norm.md)
- [Related News](https://longbridge.com/en/quote/ITRM.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/ITRM.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**